TRIB News Today: Stay Updated with the Latest Trinity Biotech plc News in Real Time
Find TRIB news now at Meyka AI. Stay informed with the latest Trinity Biotech plc stocks updates, including price news, market analysis, and expert insights.
Concord Biotech Shares Jump 5.9% After US FDA Approves Tofacitinib Arthritis Drug
Shares of Concord Biotech saw strong buying interest after a key global development. The stock rose around 5.9% in recent trading sessions after news of a US FDA approval related to its Tofacitinib-based arthritis drug. The trigger is important. The US Food and Drug Administration (FDA) approval opens doors to the world’s largest pharmaceutical market….
Hindustan Unilever Ltd Jumps 2.75% as JPMorgan Flags Premiumisation Growth
₹2,191.50. Up ₹58.70. In a single session. Hindustan Unilever Ltd (HINDUNILVR.NS) delivered one of its sharpest single-day moves in months on June 10, 2026, with the stock climbing 2.75% as fresh brokerage commentary on India’s premiumisation trend landed at exactly the right time. Hindustan Unilever Ltd gained for a fifth straight session. The stock trading…
Lloyds Banking Group PLC (LON: LLOY) Falls 0.12% as Stock Dips to 98.06 GBX Amid £5M Buyback
Lloyds Banking Group PLC shares slipped 0.12% to 98.06 GBX on June 10, 2026, as investors reacted to mixed sentiment in the UK banking sector. The move came even as the bank continued its £5M daily share buyback programme aimed at supporting shareholder value. Trading remained steady but cautious throughout the session. Market participants are…
Parabilis Medicines Targets Up to $2.3 Billion Valuation in Expanded U.S. IPO Amid Biotech Market Rally
Parabilis Medicines is aiming for a valuation of nearly $2.3 billion through an expanded U.S. initial public offering, highlighting renewed investor confidence in the biotechnology sector. The Cambridge, Massachusetts-based company increased the size of its offering as demand for biotech IPOs continues to improve following a challenging period for the industry. The company now plans…
GSK to Buy Nuvalent for $10.6 Billion, Paying $124 Per Share in All-Cash Deal
GSK has made a major move in the global pharmaceutical industry. The company has agreed to acquire Nuvalent for $10.6 billion in an all-cash deal. The offer price is $124 per share, which is about a 40% premium compared to the last closing price of Nuvalent. This is not a small deal. It is one…
GSK Plc Announces $10.6B Nuvalent Acquisition to Boost Lung Cancer Pipeline; Stock Falls 3.24%
GSK Plc moved decisively on June 9, 2026. The British drugmaker agreed to acquire US-listed cancer drug developer Nuvalent for $10.6 billion in an all-cash deal, valuing Nuvalent at approximately $124 per share, a 40% premium to its last closing price. Net of cash acquired, GSK’s actual upfront investment totals $9.4 billion. GSK Plc stock…
Panacea Biotec Soars 11.89% to 52-Week High After Launch of EU-Funded DENSTAR Project
Panacea Biotec is having its best week in years. The stock surged 11.89% to a fresh 52-week high of ₹619.05 on June 9, 2026, on the NSE, rallying from a 52-week low of ₹293.10, for an 111% climb in under twelve months. The trigger was the official launch of the DENSTAR project, a 48-month, EU-backed…
NVDA Stock Update: NVIDIA Corp at $205.10, Down 6.20% (-$13.56) as Lunit Joins AI Ecosystem Meeting in Korea
NVDA stock closed Friday, June 6, at $205.10, its worst single-day drop since February. The stock fell 6.20%, moving from $218.66 to $205.10, with a session range of $204.34 to $214.87. Total volume hit 216 million shares, 47 million above the daily average, exchanging approximately $44.23 billion in a single session. NVDA’s all-time high of…
Reeves Backs UK Growth Plan With £470m Industrial Fund, June 08
Reeves announces £350m chemicals fund and £120m ceramics support amid UK manufacturing energy cost crisis and political uncertainty.